Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey A Block

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Annals of Internal Medicine|February 21, 2018
Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline UpdateMarkus Ketteler, Geoffrey A Block, Pieter Evenepoel, et al.
Kidney International|June 26, 2017
Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it mattersMarkus Ketteler, Geoffrey A Block, Pieter Evenepoel, et al.
Journal of the American Society of Nephrology : JASN|May 14, 2015
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKDTamara Isakova, Joachim H Ix, Stuart M Sprague, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 29, 2015
Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on DialysisPatrick S Parfrey, Geoffrey A Block, Ricardo Correa-Rotter, et al.
Clinical and Translational Science|August 30, 2020
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKDJames H Lewis, Michel Jadoul, Geoffrey A Block, et al.
American Journal of Nephrology|February 7, 2018
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes StudyMelanie P Chin, George L Bakris, Geoffrey A Block, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 27, 2008
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysisMichel Chonchol, Francesco Locatelli, Hanna E Abboud, et al.
Journal of the American Society of Nephrology : JASN|May 16, 2019
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE TrialJoachim H Ix, Tamara Isakova, Brett Larive, et al.
Kidney International|August 5, 2019
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney diseasePeter Rossing, Geoffrey A Block, Melanie P Chin, et al.
JAMA|January 19, 2017
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical TrialGeoffrey A Block, David A Bushinsky, Sunfa Cheng, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Annals of Internal Medicine|February 21, 2018
Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline UpdateMarkus Ketteler, Geoffrey A Block, Pieter Evenepoel, et al.
Kidney International|June 26, 2017
Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it mattersMarkus Ketteler, Geoffrey A Block, Pieter Evenepoel, et al.
Journal of the American Society of Nephrology : JASN|May 14, 2015
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKDTamara Isakova, Joachim H Ix, Stuart M Sprague, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 29, 2015
Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on DialysisPatrick S Parfrey, Geoffrey A Block, Ricardo Correa-Rotter, et al.
Clinical and Translational Science|August 30, 2020
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKDJames H Lewis, Michel Jadoul, Geoffrey A Block, et al.
American Journal of Nephrology|February 7, 2018
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes StudyMelanie P Chin, George L Bakris, Geoffrey A Block, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 27, 2008
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysisMichel Chonchol, Francesco Locatelli, Hanna E Abboud, et al.
Journal of the American Society of Nephrology : JASN|May 16, 2019
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE TrialJoachim H Ix, Tamara Isakova, Brett Larive, et al.
Kidney International|August 5, 2019
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney diseasePeter Rossing, Geoffrey A Block, Melanie P Chin, et al.
JAMA|January 19, 2017
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical TrialGeoffrey A Block, David A Bushinsky, Sunfa Cheng, et al.
Pageof 12